Table 1. Characteristics of the study population.
| Variable | Gastric cancer patients (N = 550) | Controls (N = 550) |
|---|---|---|
| Age (years) | 63 (18, 55, 69, 87) | 59 (22, 54, 64, 84) |
| Gender | ||
| Male | 393 (71.5%) | 380 (69.1%) |
| Female | 157 (28.5%) | 170 (30.9%) |
| BMI | 21.5 (14.5, 19.6, 23.4, 32.2) | 24.4 (17.5, 22.6, 26.3, 59.7) |
| T classification | ||
| T1 | 20 (3.6%) | N/A |
| T2 | 75 (13.7%) | N/A |
| T3 | 268 (48.8%) | N/A |
| T4 | 186 (33.9%) | N/A |
| N classification | ||
| N0 | 120 (21.9%) | N/A |
| N1 | 82 (15.0%) | N/A |
| N2 | 127 (23.2%) | N/A |
| N3 | 219 (40.0%) | N/A |
| Stage | ||
| I | 41 (8.0%) | N/A |
| II | 134 (26.1%) | N/A |
| III | 315 (61.3%) | N/A |
| IV | 24 (4.7%) | N/A |
| Gastric cancer subtype | ||
| Intestinal | 286 (52.0%) | N/A |
| Diffuse | 264 (48.0%) | N/A |
| APOE genotype | ||
| ε2/ε2 | 3 (0.5%) | 1 (0.2%) |
| ε2/ε3 | 81 (14.7%) | 60 (10.9%) |
| ε2/ε4 | 7 (1.3%) | 5 (0.9%) |
| ε3/ε3 | 371 (67.5%) | 396 (72.0%) |
| ε3/ε4 | 80 (14.5%) | 85 (15.5%) |
| ε4/ε4 | 8 (1.5%) | 3 (0.5%) |
| Triglycerides (mmol/L) | 1.01 (0.39, 0.79, 1.32, 8.69) | 1.18 (0.27, 0.84, 1.63, 6.14) |
| Total cholesterol (mmol/L) | 4.67 (1.80, 3.97, 5.45, 8.85) | 5.33 (0.91, 4.63, 6.03, 11.08) |
| HDL-cholesterol (mmol/L) | 1.24 (0.47, 1.00, 1.52, 2.78) | 1.41 (0.56, 1.16, 1.74, 3.18) |
| LDL-cholesterol (mmol/L) | 3.02 (0.73, 2.51, 3.76, 7.70) | 3.52 (0.36, 2.96, 4.14, 9.14) |
| ApoA1 (g/L) | 1.06 (0.35, 0.82, 1.35, 2.29) | 1.34 (0.77, 1.17, 1.48, 4.50) |
| ApoB (g/L) | 0.91 (0.29, 0.75, 1.08, 2.10) | 0.97 (0.08, 0.83, 1.11, 1.79) |
| ApoA1/apoB ratio | 1.20 (0.25, 0.90, 1.53, 8.07) | 1.37 (0.50, 1.12, 1.76, 5.93) |
The sample median (minimum, 25th percentile, 75th percentile, maximum) is given for continuous variables. Information was unavailable regarding T classification (1 gastric cancer patient), N classification (2 gastric cancer patients), stage (36 gastric cancer patients), ApoA1 (1 control), ApoB (1 control), and ApoA1/apoB ratio (1 control).